Takeda-Nycomed cuts 2,800 mainly EU jobs to eliminate extra ¥10 billion in overlaps
This article was originally published in Scrip
Takeda is to cut its European and US workforce by 2,800 in the wake of its merger with Nycomed. It has announced the details of a rationalisation plan that will enable it to make a third more savings in Europe than it originally envisaged back in May 2011.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.